FDA
-
-
-
-
-
-
-
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics
-
-
-
-
-
-
-
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance
-
-
-
-
-
-
-
Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency¹, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Traject
-
-
-
-
-
-
-
EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three
-
-
-
-
324,678 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

